On this episode Tech Nation broadcasts from BIO 2015, the international biotechnology conference in Philadelphia. The buzz centers around a new focus on patient-oriented drug development, as well as real success with cancer immunotherapies and deep progress in rare diseases. There are signs that the industry is maturing, finally delivering on the promise of bio-pharmaceutical drugs on an unprecedented scale, while the effect of patents on emerging products is a concern, as getting drugs to humans is different than patenting a widget.

Dr. Moira Gunn speaks with:
- JIM GREENWOOD President and CEO of BIO, the Biotechnology Industry Organization as Tech Nation
- PAUL HASTINGS Chairman and President, OncoMed Pharmaceuticals and Chairnman, BIO Board of Directors’ Patient Advocacy Committee
MIKE MAY, Editorial Director of Scientific American WorldView and YALI FRIEDMAN is the head of data analytics for Scientific American WorldView, and
- GARETH WILLIAMS Partner and Patent Attorney, Marks & Clerk International Intellectual Property Firm and Editor-in-Chief, Marks & Clerk Life Sciences Report 2015 “From Rare to Routine: Medicines for Rare Diseases, Vaccines & Antibiotics.”